Clinical trial • Phase III • Endocrinology

Insulin GZR4 for Type 2 diabetes mellitus

Phase III trial of Insulin GZR4 for Type 2 diabetes mellitus. Insulin Degludec; Insulin Icodec (doses and schedules not specified in source)-controlled.

Overview

Trial Therapeutic Area
Endocrinology
Trial Disease
Type 2 diabetes mellitus
Trial Stage
Phase III
Drug Modality
Peptide/protein/enzyme

Key dates

Initial CTIS Submission Date
23-06-2025
First CTIS Authorization Date
06-08-2025

Trial design

Insulin Degludec; Insulin Icodec (doses and schedules not specified in source)-controlled Phase III trial across 1 site in Germany.

Comparator
Insulin Degludec; Insulin Icodec (doses and schedules not specified in source)

Eligibility

Recruits 14 Vulnerable population selected (isVulnerablePopulationSelected=true); no details on consent or assent handling provided in source..

Vulnerable Population
Vulnerable population selected (isVulnerablePopulationSelected=true); no details on consent or assent handling provided in source.

Recruitment

Recruitment Window Months
9

Geography

Total Number Of Sites
1
Total Number Of Participants
14

Germany

Earliest CTIS Part Ii Submission Date
31-07-2025
Latest Decision Or Authorization Date
04-12-2025
Processing Time Days
126
Number Of Sites
1
Number Of Participants
14

Sites

Site Name
PROFIL Institut fuer Stoffwechselforschung GmbH
Contact Person Name
Mila Telegravciska
Contact Person Email
mila.telegravciska@profil.com
Number Of Participants
14

Sponsor

Primary sponsor

Full Name
Gan & Lee Pharmaceuticals USA Corp.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
Insulin GZR4
Active Substance
Insulin GZR4
Modality
Peptide/protein/enzyme
Investigational Product Name
Insulin Degludec
Active Substance
Insulin Degludec
Modality
Peptide/protein/enzyme
Investigational Product Name
Insulin Icodec
Active Substance
Insulin Icodec
Modality
Peptide/protein/enzyme

Related trials

Other published trials that may interest you.